☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Infusion Time
Roche's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time Receives EMA's Approval for Relapsing or Primary Progressive Multiple S...
May 28, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.